ASCO Solid Tumors 2022 – Kohei Shitara
Kohei Shitara talks about new promising agents in the treatment of advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma and how existing drugs can blend into these new regimens. He overviews the current state of prognostic and predictive biomarkers in gastric cancer and gives an outlook on new biomarkers that are on the rise to guide therapy while finally summarizing his personal medical and scientific highlights at this year’s ASCO meeting.